TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Fusion Antibodies Plc ( (GB:FAB) ) has issued an announcement.
Fusion Antibodies plc announced it will release its unaudited interim results for the six months ended 30 September 2025 on 24 November 2025. The company will host an online live presentation for investors on 25 November 2025, providing an opportunity for stakeholders to engage with the management team and receive updates on the company’s business and current trading. This announcement underscores Fusion’s commitment to transparency and investor engagement, potentially impacting its market positioning and stakeholder relations positively.
The most recent analyst rating on (GB:FAB) stock is a Sell with a £11.50 price target. To see the full list of analyst forecasts on Fusion Antibodies Plc stock, see the GB:FAB Stock Forecast page.
Spark’s Take on GB:FAB Stock
According to Spark, TipRanks’ AI Analyst, GB:FAB is a Underperform.
Fusion Antibodies Plc’s overall stock score is primarily driven by its challenging financial performance and weak technical indicators. The company’s negative profitability and cash flow issues are significant concerns, while the bearish technical signals suggest further downside risk. The valuation metrics also reflect the company’s financial difficulties, contributing to the low overall score.
To see Spark’s full report on GB:FAB stock, click here.
More about Fusion Antibodies Plc
Fusion Antibodies plc is a Belfast-based contract research organization specializing in pre-clinical antibody discovery, engineering, and supply for therapeutic drug and diagnostic applications. Established in 2001 as a spin-out from Queen’s University Belfast, the company provides a comprehensive range of services including antibody generation, development, production, characterization, and optimization. Fusion Antibodies has a notable international client base, including eight of the top 10 global pharmaceutical companies by revenue.
Average Trading Volume: 1,077,247
Technical Sentiment Signal: Buy
Current Market Cap: £13.92M
For an in-depth examination of FAB stock, go to TipRanks’ Overview page.